OCS

NASDAQ · Pharmaceuticals

Oculis Holding Ag

Small-Cap Stocks Pharmaceutical Stocks Healthcare Stocks

$10.34

+0.20 (+1.97%)

As of Sep 22, 1:45 PM ET ·

OCS News1 articles

Oculis Shares Plunge as Eye Drop Fails Key Trial Goal

Oculis shares tumbled 23.4% after two Phase 3 trials of OCS-01 eye drops for diabetic macular edema failed to meet the main vision goal. The company will not pursue U.S. approval for this indication.